Cartesian Therapeutics (RNAC) Earnings Date & Reports

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

RNAC is expected to report earnings to fall 40.82% to -86 cents per share on August 06

Cartesian Therapeutics RNAC Stock Earnings Reports

Q2'26

Est.

$-0.86

Q1'26

Missed

by $0.51

Q4'25

Missed

by $2.54

Q3'25

Missed

by $0.48

Q2'25

Beat

by $1.30

The last earnings report on April 30 showed earnings per share of -146 cents, missing the estimate of -94 cents. With 1.98M shares outstanding, the current market capitalization sits at 172.18M.

View a ticker or compare two or three

Compare

RNAC

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for RNAC